2 assets in Inborn Mitochondrial Myopathy

Therapeutic assets addressing Inborn Mitochondrial Myopathy, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
1-(2-Deoxy-?-D-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione Inborn Mitochondrial Myopathy	Cristina Domínguez González	P2	CCC (53)
Doxecitine Inborn Mitochondrial Myopathy	Cristina Domínguez González	P2	CCC (53)